Skip to content
DataLookout
Menu

CRESTNCT07560046

Combating Related Epidemics in HCV

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Nov 30, 2030 to Nov 2029
    • Study completion moved earlier from Dec 30, 2030 to Jul 2030
  2. Notable Primary completion date: Nov 30, 2030 to Nov 2029
    • Study completion date: Dec 30, 2030 to Jul 2030
  3. Notable Eligibility criteria expanded, about 18 words
    • Interventions modified
    • Collaborators revised (9)
    • Publications: 28 to 31
  4. Notable Start date: Aug 1, 2026 to Jan 20, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 2 words
    • Interventions: Abbott Determine HIV - 1/2 Ag/Ab (Device), Abbott Determine HbsAg 2 (Device), Cepheid GeneXpert HCV Test (Device), Sofosbuvir / Velpatasvir… to Abbott Determine HIV - 1/2 Ag/Ab (Device), Abbott Determine HbsAg 2 (Device), Cepheid GeneXpert HCV Test (Device), Sofosbuvir / Velpatasvir…
    • Secondary endpoints: details revised at 11 of 20 entries
    • Publications: details revised at 28 of 28 entries
  5. Notable Primary endpoint(s) modified
    • Secondary endpoints revised (20)
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of participants who complete the Hepatitis C Virus (HCV) care cascade within 24 weeks of study entry in intervention versus Standard of Care (SOC) arm.
Timeframe: 24 weeks from study enrollment

Secondary (20)

Proportion of participants initiating same-visit direct-acting antiviral (DAA) treatment following enrollment (intervention arm only)
Proportion of participants initiating direct-acting antiviral (DAA) therapy within 12 weeks of entry
Proportion of participants initiating direct-acting antiviral (DAA) therapy within 24 weeks of entry
Time from enrollment to treatment initiation
Proportion of participants completing direct-acting antiviral (DAA) therapy within 24 weeks of entry
Show 15 moreShow less
Proportion of participants achieving sustained virologic response (SVR4+) within 60 weeks of entry
Cumulative incidence of HCV reinfection following sustained virologic response (SVR4+) within 60 weeks of entry
Cumulative retreatment following sustained virologic response (SVR4+) or relapse within 60 weeks of entry
Proportion of participants with HCV RNA not detected based on dried blood spot at week 24 and week 60
Proportion of participants who have received any HIV test result within 24 weeks of entry
Proportion of participants who initiate PrEP within 24 weeks of entry
Proportion of participants with HIV who commence direct-acting antiviral (DAA) therapy within 24 weeks of entry
Proportion of participants with HIV not on antiretroviral therapy (ART) at screening who commence ART within 24 weeks of entry
Proportion of participants with HIV on antiretroviral therapy (ART) at screening who remain on ART at week 24 and week 60
Time from enrollment to PrEP initiation
All cause and liver specific hospitalizations through week 60
All cause and liver specific mortality through week 60
On direct-acting antiviral (DAA) treatment serious suspected adverse events leading to discontinuation of sofosbuvir/velpatasvir
Adverse maternal and fetal outcomes for those on direct-acting antiviral (DAA) at any time during pregnancy
Adverse device effects related to study devices

Arms and interventions

Standard of Care (control arm)Active comparator

Participants will complete standard local clinical practice for HCV, HIV, and HBV testing and for initiation of treatment of HCV.

Single-visit POC test & treat (intervention arm)Experimental

Sites randomized to the single-visit point-of-care test (POC) \& treat arm will undergo fingerstick POC HCV RNA, HIV antibody/antigen, and HBsAg and for those with detectable HCV RNA, HCV treatment will be initiated.

Devices: Cepheid GeneXpert HCV Test

Diagnostic tests: INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test

Drugs: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Sofosbuvir/Velpatasvir/Voxilaprevir